Literature DB >> 17304174

[Levodopa modifies pain thresholds in Parkinson's disease patients].

T Slaoui1, A Mas-Gerdelat, F Ory-Magne, O Rascol, C Brefel-Courbon.   

Abstract

OBJECTIVE: To assess levodopa dose effect on pain thresholds in Parkinson's disease (PD) patients using an experimental nociceptive thermal stimulation. PATIENTS AND METHODS: We evaluated pain thresholds in 20 PD patients treated by dopaminergic drugs. We assessed heat and cold pain thresholds by using 2 different methods (method of limits and method of levels), intensity-response curve and tolerance threshold. Each PD patient was evaluated in two conditions: ON (after administration of leovdopa and OFF (after acute levodopa withdrawal). The order was randomized.
RESULTS: The mean age of patients was 652+/-9.9 years and the mean duration was 9.3+/-3.3 years. Heat pain thresholds were statistically higher in ON versus OFF condition using both methods (44.1+/-3,6 degrees C versus 42.3+/-3,1 degrees C, method of levels, p=0.02). Cold pain thresholds were statistically higher in ON versus OFF condition only using method of levels (17.9+/-4,4 degrees C versus 19.6+/-4,2 degrees C, p=0.02). Heat pain tolerance was statistically higher in ON versus OFF condition (21.4+/-21.6 seconds versus 14.7+/-20.3 seconds, p=0.02).
CONCLUSION: This study showed that levodopa increased heat and cold pain thresholds and heat pain tolrance in PD patients. This suggests that dopaminergic drugs could have an analgesic effects on PD related pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17304174     DOI: 10.1016/s0035-3787(07)90356-2

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  8 in total

1.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

Review 2.  Management of pain in Parkinson's disease.

Authors:  Munazza Sophie; Blair Ford
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 3.  Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.

Authors:  Eva Schaeffer; Daniela Berg
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

Review 4.  Pathophysiology of somatosensory abnormalities in Parkinson disease.

Authors:  Antonella Conte; Nashaba Khan; Giovanni Defazio; John C Rothwell; Alfredo Berardelli
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

5.  Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson's disease: a correlation study.

Authors:  Estelle Dellapina; Jean Pellaprat; Djilali Adel; Jerome Llido; Estelle Harroch; Jean Baptiste Martini; Aurélie Kas; Anne Sophie Salabert; Fabienne Ory-Magne; Pierre Payoux; Christine Brefel-Courbon
Journal:  J Neural Transm (Vienna)       Date:  2019-01-31       Impact factor: 3.575

6.  Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study.

Authors:  A Gerdelat-Mas; M Simonetta-Moreau; C Thalamas; F Ory-Magne; T Slaoui; O Rascol; C Brefel-Courbon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-15       Impact factor: 10.154

7.  The effects of a dopamine agonist (apomorphine) on experimental and spontaneous pain in patients with chronic radicular pain: A randomized, double-blind, placebo-controlled, cross-over study.

Authors:  May Haddad; Dorit Pud; Roi Treister; Erica Suzan; Elon Eisenberg
Journal:  PLoS One       Date:  2018-04-05       Impact factor: 3.240

8.  The Parkinson disease pain classification system: results from an international mechanism-based classification approach.

Authors:  Veit Mylius; Santiago Perez Lloret; Rubens G Cury; Manoel J Teixeira; Victor R Barbosa; Egberto R Barbosa; Larissa I Moreira; Clarice Listik; Ana M Fernandes; Diogo de Lacerda Veiga; Julio Barbour; Nathalie Hollenstein; Matthias Oechsner; Julia Walch; Florian Brugger; Stefan Hägele-Link; Serafin Beer; Alexandra Rizos; Kallol Ray Chaudhuri; Didier Bouhassira; Jean-Pascal Lefaucheur; Lars Timmermann; Roman Gonzenbach; Georg Kägi; Jens Carsten Möller; Daniel Ciampi de Andrade
Journal:  Pain       Date:  2021-04-01       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.